These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Myasthenia and the neuromuscular junction. Gilhus NE Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950 [TBL] [Abstract][Full Text] [Related]
6. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584 [TBL] [Abstract][Full Text] [Related]
7. Myasthenia gravis (first of two parts). Drachman DB N Engl J Med; 1978 Jan; 298(3):136-42. PubMed ID: 201840 [No Abstract] [Full Text] [Related]
8. Autoimmune diseases against cell surface receptors: myasthenia gravis, a prototype anti-receptor disease. De Baets MH Neth J Med; 1994 Dec; 45(6):294-301. PubMed ID: 7838246 [TBL] [Abstract][Full Text] [Related]
9. [Myasthenia, a model of a disease caused by auto-antibodies]. Goulon M; Gajdos P; Goulon-Goëau C Ann Med Interne (Paris); 1987; 138(6):444-61. PubMed ID: 2829682 [No Abstract] [Full Text] [Related]
10. How the autoimmune response to acetylcholine receptor impairs neuromuscular transmission in myasthenia gravis and its animal model. Lindstrom J Fed Proc; 1978 Dec; 37(14):2828-30. PubMed ID: 214352 [No Abstract] [Full Text] [Related]
11. [Physiopathology of myasthenia gravis. A review (author's transl)]. Bergmans J Ann Chir; 1980 Mar; 34(3):147-57. PubMed ID: 6245616 [No Abstract] [Full Text] [Related]
12. Immunopathogenesis and treatment of myasthenia gravis. Levinson AI; Zweiman B; Lisak RP J Clin Immunol; 1987 May; 7(3):187-97. PubMed ID: 3036906 [No Abstract] [Full Text] [Related]